Citi lowered the firm’s price target on BioMarin to $91 from $94 and keeps a Neutral rating on the shares. BioMarin started the year with mixed Q1 financial results and a broad pipeline rationalization, the analyst tells investors in a research note. The firm says that while the changes represent a significant strategic shift, given recent challenges, a reset was in order.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- BioMarin Reports Record Financial Results for the First Quarter 2024
- BioMarin price target raised to $110 from $100 at Cantor Fitzgerald
- Biomarin Pharmaceutical Inc. (BMRN) Q1 Earnings Cheat Sheet
- BioMarin participates in a conference call with JPMorgan.
- BioMarin presents new data for Voxzogo in achondroplasia and achondroplasia
